Literature DB >> 16143565

HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates.

Luis de la Fuente1, Carlos Toro, Vicente Soriano, M Teresa Brugal, Fernando Vallejo, Gregorio Barrio, Victoria Jiménez, Teresa Silva.   

Abstract

BACKGROUND: Although some studies have described the epidemiology of infection with HIV or hepatitis B and C in young users in Spain - one of the European countries with the highest prevalences - there are no studies of the prevalence of HTLV infection and the most important associated factors.
OBJECTIVES: To evaluate the prevalence and main determinants of HTLV-1 and HTLV-2 infection in young heroin users (including both injection (IDUs) and non-injection drug users (NIDUs)) recruited outside health care services in three of Spain's principal cities. STUDY
DESIGN: Cross-sectional cohort study. All participants (981) were street-recruited by chain referral procedures between April 2001 and December 2003. Face-to-face interviews were conducted using a structured questionnaire and dried blood spot samples were collected for serological testing.
RESULTS: No sample was positive for HTLV-1 and 27 samples were positive for HTLV-2; all of these were found only in Spanish IDUs in the cities of Madrid (17, 6.2%) and Barcelona (10, 3.5%). The only two factors significantly associated with HTLV infection in the logistic regression analysis were HIV infection (OR 5.7; 95% CI 2.2-14.8) and having injected in the last 30 days (OR 6.5; 95% CI 1.4-29.8). Having been in prison (OR 2.4; 95% CI 0.9-6.4) and HCV infection (OR 3.8; 95% CI 0.5-30.7), which were strongly and significantly associated in the bivariate analysis, were no longer significant in the logistic analysis. Almost the same variables were selected in the tree analysis, in which subjects could be classified into three groups: high prevalence (28.5%, HIV+ and HBV+ who had injected in the last 30 days), medium prevalence (17.8%) and low (<3%) or zero prevalence (HIV-, HCV- and HBV-).
CONCLUSIONS: HTLV-1 was not detected among young Spanish heroin users. HTLV-2 was not found in NIDUs (perhaps due to the low rate of sexual transmission); it was found only in IDUs from Madrid and Barcelona, but not in those from Seville. Its prevalence is very low and the main correlates of infection were HIV infection and injection as the usual route of heroin administration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143565     DOI: 10.1016/j.jcv.2005.06.006

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  10 in total

Review 1.  Innovations in health and demographic surveillance systems to establish the causal impacts of HIV policies.

Authors:  Kobus Herbst; Matthew Law; Pascal Geldsetzer; Frank Tanser; Guy Harling; Till Bärnighausen
Journal:  Curr Opin HIV AIDS       Date:  2015-11       Impact factor: 4.283

Review 2.  Hepatitis C virus/human T lymphotropic virus 1/2 co-infection: Regional burden and virological outcomes in people who inject drugs.

Authors:  Erika Castro; Elena Roger
Journal:  World J Virol       Date:  2016-05-12

3.  HTLV-2 infection in injection drug users in King County, Washington.

Authors:  Joseph R Zunt; Ken Tapia; Hanne Thiede; Rong Lee; Holly Hagan
Journal:  Scand J Infect Dis       Date:  2006

4.  Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe.

Authors:  Ene-Ly Jõgeda; Radko Avi; Merit Pauskar; Eveli Kallas; Tõnis Karki; Don Des Jarlais; Anneli Uusküla; Irja Lutsar; Kristi Huik
Journal:  Infect Genet Evol       Date:  2016-05-17       Impact factor: 3.342

5.  Policy makers ignoring science and scientists ignoring policy: the medical ethical challenges of heroin treatment.

Authors:  Dan Small; Ernest Drucker
Journal:  Harm Reduct J       Date:  2006-05-02

6.  A multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven sampling.

Authors:  Ruth Zimmermann; Ulrich Marcus; Dirk Schäffer; Astrid Leicht; Benjamin Wenz; Stine Nielsen; Claudia Santos-Hövener; R Stefan Ross; Oumaima Stambouli; Boris-Alexander Ratsch; Norbert Bannert; Claus-Thomas Bock; Claudia Kücherer; Osamah Hamouda
Journal:  BMC Public Health       Date:  2014-08-14       Impact factor: 3.295

7.  No significant HTLV seroprevalence in German people who inject drugs.

Authors:  Oliver Hohn; Stephen Norley; Claudia Kücherer; Ali Bazarbachi; Hiba El Hajj; Ulrich Marcus; Ruth Zimmermann; Norbert Bannert
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

8.  Human T-lymphotropic virus 1 and 2 among people who used illicit drugs in the state of Pará, northern Brazil.

Authors:  Aldemir B Oliveira-Filho; Ana Paula S Araújo; Andreia Polliana C Souza; Camila M Gomes; Gláucia C Silva-Oliveira; Luísa C Martins; Benedikt Fischer; Luiz Fernando A Machado; Antonio Carlos R Vallinoto; Ricardo Ishak; José Alexandre R Lemos; Emil Kupek
Journal:  Sci Rep       Date:  2019-10-14       Impact factor: 4.379

9.  Evaluation of the Inflammatory Cytokines and IL-10 Network in Individuals Co-infected With Human T-Cell Lymphotropic Virus and Hepatitis C Virus (HTLV/HCV).

Authors:  Felicidade Mota Pereira; Pablo Ivan Pereira Ramos; Monique Lirio; Ajax Mercês Atta; Isabela Silva de Oliveira; Fabio Carneiro Vosqui Nascimento; Marcelo Costa Silva; Bernardo Galvão-Castro; Maria Fernanda Rios Grassi
Journal:  Front Microbiol       Date:  2021-02-26       Impact factor: 5.640

10.  Human T-Lymphotropic Virus-1/2 Infection in Central Brazil Prisons: A Multicenter Study.

Authors:  Larissa Melo Bandeira; Marco Antonio Moreira Puga; Julio Croda; Maurício Antonio Pompílio; Carolina Amianti; Grazielli Rocha de Rezende; Ana Rita Coimbra Motta-Castro
Journal:  Front Microbiol       Date:  2022-01-21       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.